Form 8-K - Current report:
SEC Accession No. 0001193125-25-143747
Filing Date
2025-06-20
Accepted
2025-06-20 17:13:37
Documents
15
Period of Report
2025-06-17
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d877313d8k.htm   iXBRL 8-K 34029
2 EX-1.1 d877313dex11.htm EX-1.1 218152
3 EX-4.1 d877313dex41.htm EX-4.1 62347
4 EX-4.2 d877313dex42.htm EX-4.2 77021
  Complete submission text file 0001193125-25-143747.txt   616184

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA bmea-20250617.xsd EX-101.SCH 2865
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE bmea-20250617_lab.xml EX-101.LAB 18737
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE bmea-20250617_pre.xml EX-101.PRE 11717
17 EXTRACTED XBRL INSTANCE DOCUMENT d877313d8k_htm.xml XML 3760
Mailing Address 900 MIDDLEFIELD ROAD 4TH FLOOR REDWOOD CITY CA 94063
Business Address 900 MIDDLEFIELD ROAD 4TH FLOOR REDWOOD CITY CA 94063 (650) 980-9099
Biomea Fusion, Inc. (Filer) CIK: 0001840439 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40335 | Film No.: 251062279
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)